Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. PET/CT Imaging Procedure
2.3. Image Analysis
2.4. Response Assessment and Follow-Up
2.5. Statistics
3. Results
3.1. Metabolic Characteristics of Lesions at Baseline
3.2. Metabolic Response and Follow-Up
3.3. Differences in Metabolic Parameters between CMR and SMD Patients
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Murgia, G.; Denaro, N.; Boggio, F.; Nazzaro, G.; Benzecry, V.; Bortoluzzi, P.; Passoni, E.; Garrone, O.; Marzano, A. Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools, and Therapeutic Approaches. Cells 2023, 12, 2737. [Google Scholar] [CrossRef] [PubMed]
- Lear, J.T.; Corner, C.; Dziewulski, P.; Fife, K.; Ross, G.L.; Varma, S.; Harwood, C.A. Challenges and New Horizons in the Management of Advanced Basal Cell Carcinoma: A UK Perspective. Br. J. Cancer 2014, 111, 1476–1481. [Google Scholar] [CrossRef] [PubMed]
- Stătescu, L.; Trandafir, L.M.; Țarcă, E.; Moscalu, M.; Leon Constantin, M.M.; Butnariu, L.I.; Trandafirescu, M.F.; Tîrnovanu, M.C.; Heredea, R.; Pătrașcu, A.V.; et al. Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia. IJMS 2023, 24, 11176. [Google Scholar] [CrossRef] [PubMed]
- Usheva, S.; Vassilev, I.; Jelev, G.; Sedloev, T.; Dimitrov, I.; Terziev, I.; Boyadzhieva, M.; Milusheva, Y.; Troyanova, P. Surgical Management of Giant Skin Tumor—A Case Report. Ann. Chir. Plast. Esthétique 2024, 69, 154–159. [Google Scholar] [CrossRef]
- Jacobsen, A.A.; Aldahan, A.S.; Hughes, O.B.; Shah, V.V.; Strasswimmer, J. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. JAMA Dermatol. 2016, 152, 816. [Google Scholar] [CrossRef]
- Trane, L.; Salvati, L.; Silvestri, F.; Venturi, F.; Zuccaro, B.; Perillo, G.; De Giorgi, V. The Importance of Caregivers for Patients with Advanced Basal Cell Carcinoma Treated with Hedgehog-Pathway Inhibitors: An Observational Prospective Study. Eur. J. Dermatol. 2024, 34, 68–72. [Google Scholar] [CrossRef]
- Sekulic, A.; Migden, M.R.; Basset-Seguin, N.; Garbe, C.; Gesierich, A.; Lao, C.D.; Miller, C.; Mortier, L.; Murrell, D.F.; For the ERIVANCE BCC Investigators; et al. Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma: Final Update of the Pivotal ERIVANCE BCC Study. BMC Cancer 2017, 17, 332. [Google Scholar] [CrossRef]
- Sathekge, M.M.; Ankrah, A.O.; Lawal, I.; Vorster, M. Monitoring Response to Therapy. Semin. Nucl. Med. 2018, 48, 166–181. [Google Scholar] [CrossRef]
- Higgins, L.J.; Pomper, M.G. The Evolution of Imaging in Cancer: Current State and Future Challenges. Semin. Oncol. 2011, 38, 3–15. [Google Scholar] [CrossRef]
- Thacker, C.A.; Weiss, G.J.; Tibes, R.; Blaydorn, L.; Downhour, M.; White, E.; Baldwin, J.; Von Hoff, D.D.; Korn, R.L. 18-FDG PET/CT Assessment of Basal Cell Carcinoma with Vismodegib. Cancer Med. 2012, 1, 230–236. [Google Scholar] [CrossRef]
- Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.G.; Giammarile, F.; Tatsch, K.; Eschner, W.; Verzijlbergen, F.J.; Barrington, S.F.; Pike, L.C.; Weber, W.A.; et al. FDG PET/CT: EANM Procedure Guidelines for Tumour Imaging: Version 2.0. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 328–354. [Google Scholar] [CrossRef] [PubMed]
- Liu, F.; Gu, B.; Li, N.; Pan, H.; Chen, W.; Qiao, Y.; Song, S.; Liu, X. Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma. Front. Oncol. 2022, 12, 862473. [Google Scholar] [CrossRef] [PubMed]
- Leong, W.L. From RECIST to PERCIST: Navigating the Landscape of Tumor Response Assessment. Eur. Radiol. 2023, 34, 3656–3658. [Google Scholar] [CrossRef] [PubMed]
- Rowe, S.P.; Pomper, M.G. Molecular Imaging in Oncology: Current Impact and Future Directions. CA Cancer J. Clin. 2022, 72, 333–352. [Google Scholar] [CrossRef]
- Filippi, L.; Biancone, L.; Petruzziello, C.; Schillaci, O. Tc-99m HMPAO-Labeled Leukocyte Scintigraphy with Hybrid SPECT/CT Detects Perianal Fistulas in Crohn Disease. Clin. Nucl. Med. 2006, 31, 541–542. [Google Scholar] [CrossRef]
- Galbán, C.J.; Galbán, S.; Van Dort, M.E.; Luker, G.D.; Bhojani, M.S.; Rehemtulla, A.; Ross, B.D. Applications of Molecular Imaging. In Progress in Molecular Biology and Translational Science; Elsevier: Amsterdam, The Netherlands, 2010; Volume 95, pp. 237–298. ISBN 978-0-12-385071-3. [Google Scholar]
- Berghmans, T.; Dusart, M.; Paesmans, M.; Hossein-Foucher, C.; Buvat, I.; Castaigne, C.; Scherpereel, A.; Mascaux, C.; Moreau, M.; Roelandts, M.; et al. Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Is of Prognostic Value for Survival in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J. Thorac. Oncol. 2008, 3, 6–12. [Google Scholar] [CrossRef]
- Surov, A.; Meyer, H.J.; Wienke, A. Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer. Transl. Oncol. 2019, 12, 375–380. [Google Scholar] [CrossRef]
- Herraez, I.; Bento, L.; Daumal, J.; Repetto, A.; Del Campo, R.; Perez, S.; Ramos, R.; Ibarra, J.; Mestre, F.; Bargay, J.; et al. Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma. J. Clin. Med. 2021, 10, 4396. [Google Scholar] [CrossRef]
- Jin, A.; Lin, X.; Yin, X.; Cui, Y.; Ma, L. Prognostic Value of MTV and TLG of 18 F-FDG PET in Patients with Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Medicine 2022, 101, e30798. [Google Scholar] [CrossRef]
- Lee, J.-W.; Park, J.-Y.; Lee, H.J.; Lee, J.J.; Moon, S.H.; Kang, S.Y.; Cheon, G.J.; Chung, H.H. Preoperative [18F]FDG PET/CT Tumour Heterogeneity Index in Patients with Uterine Leiomyosarcoma: A Multicentre Retrospective Study. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1309–1316. [Google Scholar] [CrossRef]
- Lovinfosse, P.; Hatt, M.; Visvikis, D.; Hustinx, R. Heterogeneity Analysis of 18F-FDG PET Imaging in Oncology: Clinical Indications and Perspectives. Clin. Transl. Imaging 2018, 6, 393–410. [Google Scholar] [CrossRef]
- Lian, W.; Liu, C.; Gu, B.; Zhang, J.; Lu, L.; Pan, H.; Yao, Z.; Wang, M.; Song, S.; Zhang, Y.; et al. The Early Prediction of Pathological Response to Neoadjuvant Chemotherapy and Prognosis: Comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer Criteria in Breast Cancer. Nucl. Med. Commun. 2020, 41, 280–287. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.D.; Kim, B.J.; Kim, H.S.; Kim, J.H. Comparison of the Morphologic Criteria (RECIST) and Metabolic Criteria (EORTC and PERCIST) in Tumor Response Assessments: A Pooled Analysis. Korean J. Intern. Med. 2019, 34, 608–617. [Google Scholar] [CrossRef] [PubMed]
- Pinker, K.; Riedl, C.; Weber, W.A. Evaluating Tumor Response with FDG PET: Updates on PERCIST, Comparison with EORTC Criteria and Clues to Future Developments. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 55–66. [Google Scholar] [CrossRef]
- Lasnon, C.; Quak, E.; Le Roux, P.-Y.; Robin, P.; Hofman, M.S.; Bourhis, D.; Callahan, J.; Binns, D.S.; Desmonts, C.; Salaun, P.-Y.; et al. EORTC PET Response Criteria Are More Influenced by Reconstruction Inconsistencies than PERCIST but Both Benefit from the EARL Harmonization Program. EJNMMI Phys. 2017, 4, 17. [Google Scholar] [CrossRef]
- Shang, J.; Ling, X.; Zhang, L.; Tang, Y.; Xiao, Z.; Cheng, Y.; Guo, B.; Gong, J.; Huang, L.; Xu, H. Comparison of RECIST, EORTC Criteria and PERCIST for Evaluation of Early Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1945–1953. [Google Scholar] [CrossRef]
- Jain, S.; Song, R.; Xie, J. Sonidegib: Mechanism of Action, Pharmacology, and Clinical Utility for Advanced Basal Cell Carcinomas. OncoTargets Ther. 2017, 10, 1645–1653. [Google Scholar] [CrossRef]
- Spallone, G.; Carbone, A.; Sperati, F.; Frascione, P.; Eibenschutz, L. Clinical Determinants of Clinical Response to Sonidegib in Advanced Basal Cell Carcinoma: A Monocenter Experience. Eur. Rev. Med. Pharmacol. Sci. 2024, 28, 2923–2928. [Google Scholar] [CrossRef]
- Alfieri, S.; Romanò, R.; Marceglia, S.; De Giorgi, V.; Peris, K.; Sollena, P.; Piccerillo, A.; Moro, R.; Gualdi, G.; Ascierto, P.A.; et al. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? Oncologist 2024, 29, e699–e707. [Google Scholar] [CrossRef]
- Liu, Y.; Ding, H.; Wan, Z.; Fan, D.; Huang, Z. Malignant Melanoma of the External Auditory Canal on 68 Ga-FAPI PET/CT. Clin. Nucl. Med. 2023, 48, 532–533. [Google Scholar] [CrossRef]
- Filippi, L.; Dimitrakopoulou-Strauss, A.; Evangelista, L.; Schillaci, O. Long Axial Field-of-View PET/CT Devices: Are We Ready for the Technological Revolution? Expert Rev. Med. Devices 2022, 19, 739–743. [Google Scholar] [CrossRef] [PubMed]
- Amrane, K.; Meur, C.L.; Thuillier, P.; Berthou, C.; Uguen, A.; Deandreis, D.; Bourhis, D.; Bourbonne, V.; Abgral, R. Review on Radiomic Analysis in 18F-Fluorodeoxyglucose Positron Emission Tomography for Prediction of Melanoma Outcomes. Cancer Imaging 2024, 24, 87. [Google Scholar] [CrossRef] [PubMed]
Pt/Sex | Age | Comorbidities | Previous Therapies | Histotype | Dermatoscopy | Location/Number of Lesions |
---|---|---|---|---|---|---|
1, F | 74 | Depression, diabetes | None | Nodular | Small ulcerations, telangiectasias, arborizing vessels | Ear, bilateral face n = 3 |
2, M | 85 | Hypertension, BHP | None | Nodular, invasive | Telangiectasias, arborizing vessels, blue-gray ovoid nests | Face, n = 3 |
3, M | 77 | Hypertension, BHP, UP | PDT | Nodular, ulcerative | Telangiectasias, arborizing vessels, ulceration | Ear, bilateral n = 2 |
4, M | 89 | Hypertension | ECT | Nodular, invasive | Telangiectasias, arborizing vessels, blue-gray ovoid nests | Ear, bilateral n = 2 |
Pt | PET Response | SUVmax | SUVmean | HI | MTV (cc) | TLG (g/mL) |
---|---|---|---|---|---|---|
1 | CMR | 6.5 | 2.9 | 2.2 | 1.3 | 3.7 |
2 | CMR | 5.1 | 3.2 | 1.6 | 0.5 | 1.6 |
3 | SMD | 9.1 | 4 | 2.2 | 4.4 | 17.9 |
4 | SMD | 16.9 | 10.8 | 1.5 | 1 | 11.8 |
9.4 ± 4.5, 7.8 * | 5.2 ± 3.2, 3.6 * | 1.8 ± 0.3, 1.9 * | 1.8 ± 1.7, 1.1 * | 8.7 ± 6.5, 7.7 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Proietti, I.; Filippi, L.; Bagni, O.; Potenza, C. Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study. J. Clin. Med. 2024, 13, 5087. https://doi.org/10.3390/jcm13175087
Proietti I, Filippi L, Bagni O, Potenza C. Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study. Journal of Clinical Medicine. 2024; 13(17):5087. https://doi.org/10.3390/jcm13175087
Chicago/Turabian StyleProietti, Ilaria, Luca Filippi, Oreste Bagni, and Concetta Potenza. 2024. "Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study" Journal of Clinical Medicine 13, no. 17: 5087. https://doi.org/10.3390/jcm13175087